SCHEMBL3230745

SCHEMBL3230745

CN(c1ccc2cccc(O)c2n1)c1ccc2cccc(O)c2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 2/20 0.58
PLAU P00749 1/20 0.53
NCF1 P14598 1/20 0.53
ALOX12 P18054 3/20 0.52
ALDH1A1 P00352 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
KDM4E B2RXH2 8/20 0.49
KMT2A Q03164 6/20 0.49
SOS2 Q07890 1/20 0.49
PIM1 P11309 1/20 0.47
TSHR P16473 2/20 0.47
MMP2 P08253 1/20 0.47
CHRM1 P11229 1/20 0.47
COMT P21964 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8344571 0.89 METAP2 (0.58) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL4285012 0.78 METAP2 (0.64) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL12827741 0.77 METAP2 (0.46) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL12747684 0.76 METAP2 (0.45) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL359691 0.75 METAP2 (0.47) METAP2PLAUNCF1ALOX12ALDH1A1
8-Hydroxy Quinaldine SCHEMBL29483489 0.74 METAP2 (1.00) METAP2PLAUNCF1ALOX12ALDH1A1
8-Hydroxy Quinaldine SCHEMBL297247 0.74 METAP2 (1.00) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL18131613 0.73 METAP2 (0.53) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL5671692 0.73 METAP2 (0.45) METAP2PLAUNCF1ALOX12ALDH1A1
SCHEMBL21767732 0.73 METAP2 (0.63) METAP2PLAUNCF1ALOX12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009140215-A2 METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS GERAGHTY, ERIN (US) 2009-11-19 WO claimed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-9302993-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2016-04-05 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PRANA BIOTECHNOLOGY LIMITED (AU) 2015-11-26 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-9169211-B2 8-hydroxy quinoline derivatives PRANA BIOTECHNOLOGY LIMITED (AU) 2015-10-27 US disclosed
US-9163018-B2 Method of treatment of age-related macular degeneration (AMD) PRANA BIOTECHNOLOGY INC. (AU) 2015-10-20 US disclosed
US-7132576-B2 Method for isomerizing allyl alcohols BASF AKTIENGESELLSCHAFT (DE) 2006-11-07 US disclosed
US-20050101807-A1 Method for isomerizing allyl alcohols BASF AKTIENGESELLSCHAFT (DE) 2005-05-12 US disclosed
US-6743526-B2 STABLE ORGANOLUMINESCENT COMPOUNDS, E.G., A CHROMONE ALUMINUM OR ZINC CHELATE, BETWEEN A HOLE INJECTION ELECTRODE AND AN ELECTRON INJECTION ELECTRODE; CRYSTALLIZATION INHIBITION; DURABILITY; NO SHORT CIRCUITS; OXIDATION RESISTANCE SANYO ELECTRIC CO., LTD. (JP) 2004-06-01 US disclosed
US-20030170495-A1 Organic electroluminescent device SANYO ELECTRIC CO., LTD. (JP) 2003-09-11 US disclosed
US-6555253-B2 Emitting layer and carrier transport layer using organic material between hole injection electrode and electron injection electrode, wherein chelate compound of chromone derivative with zinc is used as organic material in one layer SANYO ELECTRIC CO., LTD. (JP) 2003-04-29 US disclosed
US-20020081453-A1 Emitting layer and carrier transport layer using organic material between hole injection electrode and electron injection electrode, wherein chelate compound of chromone derivative with zinc is used as organic material in one layer SANYO ELECTRIC CO., LTD. (JP) 2002-06-27 US disclosed
US-6294273-B1 EXHIBITS HOLE-INJECTING, HOLE-TRANSPORTING, ELECTROLUMINESCENT, ELECTRON-TRANSPORTING, AND ELECTRON-INJECTING FUNCTIONS, WHEREIN THE HOLE INJECTION ZONE CONTAINS AN UNCHARGED OR CATIONIC POLYTHIOPHENE BAYER AKTIENGESELLSCHAFT (DE) 2001-09-25 US disclosed
EP-1026924-A1 ORGANIC ELECTROLUMINESCENT DEVICE Sanyo Electric Co., Ltd. (JP) 2000-08-09 EP disclosed
WO-2000008128-A1 FABRIC CARE COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2000-02-17 WO disclosed
EP-0964459-A2 Electroluminescent devices containing N-alkyl-2,2'-imino-bis-(8-hydroxy-quinoline) metal complexes Bayer Aktiengesellschaft (DE) 1999-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335635-A1 8-HYDROXY QUINOLINE DERIVATIVES PARK7, COQ8A, NLN METAP2 1832/4885PLAU 2218/4885NCF1 2693/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT METAP2 1330/4885PLAU 3003/4885NCF1 2599/4885
US-20050101807-A1 Method for isomerizing allyl alcohols ADH1A, ADH1C, ADH5 METAP2 680/4885PLAU 4336/4885NCF1 1247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.